Navigation Links
Array BioPharma Announces Updates on ARRY-520 Clinical Data at the 2013 International Myeloma Workshop
Date:4/4/2013

BOULDER, Colo., April 4, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced that results from two ongoing ARRY-520 clinical trials in multiple myeloma (MM) were presented at the 2013 International Myeloma Workshop in Kyoto, Japan. ARRY-520 is a potent, selective KSP inhibitor with a mechanism of action distinct from other drugs used to treat MM that continues to advance in clinical trials.

(Logo:  http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)

Results on the following trials presented at the meeting include:

ARRY-520 Single Agent Clinical Trial in Patients with Relapsed or Refractory Multiple Myeloma (MM) (Protocol # ARRAY-520-212)

  • ARRY-520 demonstrated single agent activity in heavily pretreated patients, with 19 months median Overall Survival and a 16% Overall Response Rate.  These results are similar to those for recently approved products Kyprolis® (carfilzomib) and Pomalyst® (pomalidomide) as single agents in a similar patient population.
  • ARRY-520 was generally well tolerated, with the predominant adverse events being transient and non-cumulative neutropenia and thrombocytopenia that were readily managed with growth factors and supportive care.
  • Consistent with other reported ARRY-520 study results, there was a low-incidence of non-hematologic adverse events with no treatment-related neuropathy observed.
  • Further data on a potential patient selection marker was also presented.  Patients with normal levels of alpha-1-acid glycoprotein (AAG) had a longer median Overall Survival (20.2 months vs 4.5 months), improved median Event Free Survival (5.3 months vs. 2.4 months) and greater Overall Response Rate (24% vs 0%) compared to patients with ele
    '/>"/>

  • SOURCE Array Biopharma
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Global Array Instrument Market is Expected to Reach USD 3.2 Billion Globally in 2017: Transparency Market Research
    2. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2013
    3. Array BioPharma To Present Clinical Data On ARRY-797 At The 2012 American College Of Rheumatology Annual Meeting
    4. Array BioPharma Announces Proposed Public Offering Of Common Stock
    5. Array BioPharma Announces Pricing Of Public Offering Of Common Stock
    6. Array BioPharma To Present At The Piper Jaffray Annual Healthcare Conference
    7. InternetArray Collaborates with Health Sciences Group to Fund Medical Marijuana Social Media/Mobile Apps Development
    8. Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
    9. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
    10. Array BioPharma To Present At The Cowen Annual Health Care Conference
    11. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... YORK , January 15, 2014 ... Ltd., the exclusive worldwide distributor of highly sophisticated agro-breeding ... on January 7, 2014, the Company,s board of directors ... Weiner as its new member of the board. ...
    (Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
    (Date:1/15/2014)... The Cadence Fitness & Health Center has been ... Fitness Association, a non-profit organization assisting medically integrated health ... Cadence Fitness & Health Center is the only certified ... the Chicagoland area. "The certification means the ...
    Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3
    ... , ... ... ... ...
    ... ... ... ... ...
    Cached Medicine Technology:Massachusetts Institute of Technology (MIT) to Launch New Brain Research Effort with Acquisition of Elekta MEG Technology 2Massachusetts Institute of Technology (MIT) to Launch New Brain Research Effort with Acquisition of Elekta MEG Technology 3Massachusetts Institute of Technology (MIT) to Launch New Brain Research Effort with Acquisition of Elekta MEG Technology 4Massachusetts Institute of Technology (MIT) to Launch New Brain Research Effort with Acquisition of Elekta MEG Technology 5Massachusetts Institute of Technology (MIT) to Launch New Brain Research Effort with Acquisition of Elekta MEG Technology 6Massachusetts Institute of Technology (MIT) to Launch New Brain Research Effort with Acquisition of Elekta MEG Technology 7Massachusetts Institute of Technology (MIT) to Launch New Brain Research Effort with Acquisition of Elekta MEG Technology 8Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus 2Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus 3Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus 4Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus 5
    (Date:7/9/2014)... Health Organization recommends that youth participate in a minimum ... (MVPA) each day. Studies have shown that youth ... Therefore, it stands to reason that increasing outdoor time ... new study scheduled for publication in The Journal ... after school was positively associated with MVPA. , Drs. ...
    (Date:7/9/2014)... (PHILADELPHIA) Researchers at the Perelman School of Medicine ... Roswell Park Cancer Institute have received an $8 million ... the effects of photodynamic light therapy (PDT) in patients ... cancer that most often manifests itself in the lining ... exposure to asbestos. The grant will fund a clinical ...
    (Date:7/9/2014)... of lung cancer, researchers have uncovered mutations in a ... The new knowledge may expand treatments for patients because ... available or are in clinical trials. , Reporting July ... Genome Atlas (TCGA), including researchers at Washington University School ... other institutions, studied tumors from 230 patients with lung ...
    (Date:7/9/2014)... in policing injection drug users in Russia might ... , A study, conducted by researchers from Boston ... collaboration with St. Petersburg Pavlov State University, sought ... the health outcomes of a cohort of HIV-positive ... Those who were arrested by police were more ...
    (Date:7/9/2014)... July 9, 2014 There has been a sharp ... Southwestern Medical Center using MyChart, the online, interactive service ... communicate with their healthcare providers, schedule appointments, and renew ... patients actively using MyChart each year increased ... increased more than 10-fold, according to a study by ...
    Breaking Medicine News(10 mins):Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Lung cancer study hints at new treatments 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3
    ... , LYNBROOK, N.Y., Sept. 16 ... a biopharmaceutical company developing first-in-class collagenase-based products, today announced ... Food and Drug Administration,s (FDA) unanimously recommended by a ... histolyticum), a novel, first-in-class, orphan-designated, biologic, be granted marketing ...
    ... published online today [Thursday] estimates nearly 45,000 annual deaths are ... two and a half times higher than an estimate from ... study, "Health Insurance and Mortality in U.S. Adults," appears in ... Public Health . The Harvard-based researchers found that uninsured, ...
    ... , SAN FRANCISCO, Sept. 21 Medithrive, Inc., ... its state of the art dispensary, offering patients a beautiful ... of medicinal marijuana products. , , ... 16th, in San Francisco, CA, has positioned itself as the ...
    ... post-menopausal women with early breast cancer to the drug exemestane ... keeping them on tamoxifen for five years improves the chance ... for at least the next six years. "These ... mid-way through the five-year tamoxifen treatment plan provides a clear ...
    ... CINCINNATICancer predisposition resulting from the presence of a ... researchers at the University of Cincinnati (UC) have ... risk for development of cancer in individuals harboring ... a result of environmental exposure. Peter Stambrook, PhD, ...
    ... NEW YORK, Sept. 21 In a bid ... online auction of the Ysio Digital Radiology System. As the ... N.Y., presented them a check for $285,309. , , ... , http://inr.mediaseed.tv/oneClip_C/?feed=hK4UKEtcAILqy08qpCX6wBwEMnTvqjZg , , ...
    Cached Medicine News:Health News:FDA Advisory Committee Unanimously Recommends Approval of XIAFLEX(TM) for Treatment of Dupuytren's Disease 2Health News:FDA Advisory Committee Unanimously Recommends Approval of XIAFLEX(TM) for Treatment of Dupuytren's Disease 3Health News:45,000 excess deaths annually linked to lack of health insurance: Harvard study 2Health News:Switching early breast cancer patients to exemestane improves long-term survival 2Health News:Cancer predisposition from genetic variation shows strong gender bias 2
    ... Tests are available in 14 configurations including ... using Microgenics Antibody Technology, the SureStep™ MDMA ... care immunoassay targeted to detect MDMA that ... MDEA but no cross-reactivity to any isomer ...
    ... Our most popular onsite test! QuickScreen™ ... the urine sample, and your choice of ... QuickScreen™ multi-panels offer total flexibility for your ... into the specimen and the built-in timer ...
    ... products, SEDIPLAST® is a completely closed ... protect laboratory personnel from the risk ... a uniquely designed erythrocyte sedimentation rate ... and convenience as well as reliable ...
    ... guaiac as a test for the presence of ... compounds present in guaiac to quinones, resulting in ... is present, the heme portion of the hemoglobin ... the release of oxygen from hydrogen peroxide which ...
    Medicine Products: